Evidence map›Paper›PMID 35731163›Full record

ArticleEmerging infectious diseases2022

Targeted Screening for Chronic Q Fever, the Netherlands.

Daphne F M Reukers, Pieter T de Boer, Alfons O Loohuis, Peter C Wever, Chantal P Bleeker-Rovers, Arianne B van Gageldonk-Lafeber, Wim van der Hoek, Aura Timen

Open access · diamondAbstract read
In one paragraph

Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daphne F M Reukers
Pieter T de Boer
Alfons O Loohuis
Peter C Wever
Chantal P Bleeker-Rovers
Arianne B van Gageldonk-Lafeber
Wim van der Hoek
Aura Timen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of and treatment for chronic Q fever might prevent potentially life-threatening complications. We performed a chronic Q fever screening program in general practitioner practices in the Netherlands 10 years after a large Q fever outbreak. Thirteen general practitioner practices located in outbreak areas selected 3,419 patients who had specific underlying medical conditions, of whom 1,642 (48%) participated. Immunofluorescence assay of serum showed that 289 (18%) of 1,642 participants had a previous Coxiella burnetii infection (IgG II titer >1:64), and 9 patients were suspected of having chronic Q fever (IgG I y titer >1:512). After medical evaluation, 4 of those patients received a chronic Q fever diagnosis. The cost of screening was higher than estimated earlier, but the program was still cost-effective in certain high risk groups. Years after a large Q fever outbreak, targeted screening still detected patients with chronic Q fever and is estimated to be cost-effective.

Indexed as

Coxiella burnetiiQ FeverAntibodies, BacterialHumansImmunoglobulin GNetherlandsAntibodies, BacterialImmunoglobulin Ganeurysmbacteriachronic Q fevercost effectivenessCoxiella burnetiigeneral practitionerheart valve diseaseimmunocompromised patientQ feverscreening programtargeted screeningthe Netherlandsvascular disease

Identifiers

PMID35731163
PMCPMC9239892
OpenAlexW4283213256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.